Drug targets and predictive biomarkers in the management of metastatic melanoma
Jaykumar Thumar, Eva Giesen, Harriet M KlugerYale Cancer Center, Yale School of Medicine, New Haven, CT, USAAbstract: Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently...
Main Authors: | Thumar J, Giesen E, Kluger HM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-09-01
|
Series: | Pharmacogenomics and Personalized Medicine |
Online Access: | http://www.dovepress.com/drug-targets-and-predictive-biomarkers-in-the-management-of-metastatic-a11148 |
Similar Items
-
Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
by: Brenda Leeneman, et al.
Published: (2020-04-01) -
Targeted agents for the treatment of metastatic melanoma
by: Monzon JG, et al.
Published: (2012-03-01) -
Mitochondria-targeted therapy for metastatic melanoma
by: Kloepping, Kyle Christohper
Published: (2015) -
Molecular targeted therapies in metastatic melanoma
by: Chakraborty R, et al.
Published: (2013-06-01) -
FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
by: A. Flaus, et al.
Published: (2021-09-01)